At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 461 enrolled

Drug / intervention

Saxagliptin +5 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02284893

NCT02284893Phase 3Completed

Compare CT.gov

A 26-week International, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3bTrial With a Blinded 26-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

AstraZeneca·interventional·Posted Nov 6, 2014·Updated Jun 1, 2018

In Brief

A Phase 3 clinical trial evaluating Saxagliptin, Dapagliflozin, and 4 other interventions for Type 2 Diabetes. Completed, enrolled 461 participants across 79 sites in 6 countries.

Detailed Summary

Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsType 2 Diabetes

CountriesHungary, Mexico, Poland, Romania, South Africa, United States

Collaborators--

Timeline

Phase 3CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartSep 2014

First PostedNov 2014

Primary CompletionSep 2016

TodayJul 2026

First PostedNov 6, 2014

Enrollment StartSep 9, 2014

Primary CompletionSep 20, 2016

TodayJul 2, 2026

Enrollment to primary: 2.0 yearsPosted 11.7 years ago